Author Archives: Vicki Colledge

At the end of March, more than 90 BHD researchers, clinicians and patients attended the Fourth BHD Symposium, which was held in Cincinnati, Ohio, USA. The Symposium was the largest BHD meeting to date and it was a huge success. … Continue reading →

At the beginning of March, Amsterdam hosted the 10th International Congress on Targeted Anticancer Therapies, organised by the NDDO Education Foundation. The congress discussed all aspects of targeted therapy, from the identification of targets and the design of drugs, to … Continue reading →

We are here live at the Fourth BHD Symposium, at the University of Cincinnati. The University of Cincinnati has not only been called one of the world’s most beautiful campuses (by Forbes magazine), but also has an illustrious history in … Continue reading →

Recent advances in DNA sequencing have led to the discovery of genes and mutations which drive tumourigenesis. In this blog, we have previously described papers by Varela et al. (2011), Dalgliesh et al. (2011) and Guo et al. (2011) which … Continue reading →

Hypoxia Inducible Factor (HIF) regulates key processes within the cell and its dysregulation is involved in the development of renal cell carcinoma (RCC), including those associated with VHL, HLRCC, TSC and also BHD syndrome. HIF is a potential therapeutic target … Continue reading →

The Fourth BHD Symposium is fast approaching and there are now only 5 days left to submit an abstract. Researchers wanting to present at the symposium, either through a poster or oral presentation, have until the end of the day … Continue reading →

This week we highlight the work of Dr Tim Cash, who worked on BHD syndrome as part of his PhD studies in the lab of Professor Celeste Simon at the Abramson Family Cancer Research Institute, University of Pennsylvania. Dr Cash … Continue reading →

We are delighted to announce further details for the Fourth BHD Symposium, which will be held in Cincinnati, Ohio, USA on 28th-30th March 2012. The meeting will take place in the Vontz Center for Molecular Studies at the University of … Continue reading →

Late last year, the European Society of Gene and Cell Therapy and the British Society for Gene Therapy hosted a joint annual congress in Brighton, UK. The congress covered all aspects of gene and cell therapy and there were also … Continue reading →

Many studies into BHD syndrome have investigated the prevalence of pneumothorax and renal cell carcinoma amongst FLCN mutation carriers. Previous estimations of the RCC risk have varied from 6.5% to 34% (Toro et al., 2008), and for pneumothorax, from 24% … Continue reading →